Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the best biotech stocks on this list.

TheFly reported on June 10 that UBS increased its price target on CLDX to $45 from $38 while maintaining a Buy rating on the shares. The firm noted that Barzolvolimab’s Phase 3 chronic spontaneous urticaria (CSU) program has a favorable development outlook and could support a potential approval in 2027.

Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?

In addition to that, more recently, on June 14, Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented updated long-term findings from its Phase 2 study of barzolvolimab during a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting. The results showed that barzolvolimab provided rapid and sustained improvements in angioedema symptoms among patients with chronic spontaneous urticaria who had not responded adequately to antihistamine treatment. The benefits remained evident seven months after patients completed dosing, highlighting the potential durability of the treatment effect. The findings further support barzolvolimab’s ability to move CSU treatment beyond symptom management toward disease modification and reinforce continued evaluation in ongoing Phase 3 CSU trials.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a clinical-stage biopharmaceutical company developing antibody therapies for inflammatory and autoimmune diseases, led by barzolvolimab for mast cell–driven conditions.

While we acknowledge the risk and potential of CLDX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CLDX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1